Single-Photon Emission Computed Tomography (SPECT)
JAMA 263:561-564, Holman,B.L.&Tumeh,S.S., 1990
Alzheimers Disease
Lancet 397:1577-1590, Scheltens, P.,et al, 2021
Alzheimer Disease
JAMA 287:2335-2338, Cummings,J.L. &Cole,G., 2002
Prospective CT Confirms Differnces Between Vascular and Alzheimer's Dementia
Stroke 26:735-742, Meyer,J.S.,et al, 1995
Differential Diagnosis in Dementia, Principal Components Analysis of Clinical Data From a Population Survey
Arch Neurol 50:72-77, Jorm,A.F.,et al, 1993
Prevalence of Amyloid PET Positivity in Dementia Syndromes
JAMA 313:1939-1949,1913, Ossenkoppele, R.,et al, 2015
PET Imaging for Alzheimer Disease: Are Its Benefits Worth the Cost?
JAMA 309:1099-1100, Mitka, M., 2013
Predicting Alzheimer Disease with �-Amyloid Imaging: Results from the Australian Imaging, Biomarkers, and Lifestyle Study of Ageing
Ann Neurol 74:905-913, Rowe, C.C.,et al, 2013
Brain Amyloid Imaging - FDA Approval of Florbetapir F18 Injection
NEJM 367:885-887, Yang, L.,et al, 2012
Changing Concepts of Alzheimer Disease
JAMA 35:2458-2459, McKhann, G.M., 2011
PET of Brain Amyloid and Tau in Mild Cognitive Impairment
NEJM 355:2652-2663, Small,G.W.,et al, 2006
Neuroimaging and Early Diagnosis of Alzheimer Disease: A Look to the Future
Radiology 226:315-336, Petrella,J.R.,et al, 2003
Early Alzheimer's Disease
NEJM 349:1056-1063, Kawas,C.H., 2003
Utility of Clinical Criteria in Differentiating Frontotemporal Lobar Degeneration (FTLD) From AD
Neurol 58:1608-1615, Rosen,H.J.,et al, 2002
Potentially Reversible Conditions in 1000 Consecutive Memory Clinic Patients
JNNP 73:390-394, Hejl,A.,et al, 2002
Evaluation of CSf-tau and CSF-AB42 as Diagnostic Markers for Alzheimer Disease in Clinical Practice
Arch Neurol 58:373-379,349, Andreasen,N.,et al, 2001
An 80-Year-Old Man With Memory Loss
JAMA 283:1046-1053, Larson,E.B., 2000
Diagnosis, Management, and Treatment of Alzheimer Disease, A Guide for the Internist
Arch Int Med 159:789-798, Richards,S.S.&Hendrie,H.C., 1999
A Clinical Role for 99mTC-HMPAO SPECT in the Investigation of Dementia
JNNP 64:306-313, Talbot,P.R.,et al, 1998
Preclinical Prediction of Alzheimer's Disease Using SPECT
Neurol 50:1563-1571, Johnson,K.A.,et al, 1998
Longitudinal Study of CSF Levels of Tau, A beta 1-40, and A beta 1-42 (43) in Alzheimer's Disease
Ann Neurol 44:17-26, 61998., Kanai,M.,et al, 1998
New Neuropathological Criteria for Alzheimer Disease
Arch Neurol 55:1174-1176, Hyman,B.T., 1998
Assessment of CSF Levels of Tau Protein in Mildly Demented Patients with Alzheimer's Disese
Neurol 48:632-635, Galasko,D.,et al, 1997
Incorrect Diagnosis of Alzheimer's Disease:A Clinicopathologic Study
Arch Neurol 53:35-42, Klatka,L.A.,et al, 1996
Preclinical Evidence of Alzheimer's Disease in Persons Homozygous for the e4Allele for Apolipoprotein E
NEJM 334:752-758, 7911996., Reiman,E.M.,et al, 1996
Diagnostic Value of SPECT with Tc 99m HMPAO in Alzheimer's Disease:A Population-Based Study
Neurol 44:454-461, Claus,J.J.,et al, 1994
Blinded Clinical Evaluation of Positron Emission Tomography for Diagnosis of Probable Alzheimer's Disease
Neurol 42:765-770, Powers,W.J.,et al, 1992
Detection in Life of Confirmed Alzheimer's Disease, Medial Temporal Lobe Atrophy by Computed Tomography
Lancet 340:1179-1183, Jobst,K.A.,et al, 1992
A 10-Item Smell Identification Scale Related to Risk for Alzheimers Disease
Ann Neurol 58:155-160, Taberr,M.H.,et al, 2005
Magnetic Resonance Spectroscopy in AD
Neurol 56:592-598, Valenzuela,M.J.,et al, 2001
Altered Brain Activation in Cognitively Intact Individuals at High Risk for Alzheimer's Disease
Neurol 53:1391-1396, Smith,C.D.,et al, 1999
Utility of the Apolipoprotein E Genotype in the Diagnosis of Alzheimer's Disease
NEJM 338:506-511, Mayeux,R.,et al, 1998
The Clinical Introduction of Genetic Testing for Alzheimer Disease, An Ethical Perspective
JAMA 277:832-836, Post,S.G.,et al, 1997
Criteria for Alzheimer's Disease and the Nosology of Dementia with Lewy Bodies
Neurol 48:126-132, Hansen,L.A.&Samuel,W., 1997
Pupil Dilation to Tropicamide is not Specific for Alzheimer Disease
Arch Neurol 54:841-844, Growdon,J.H.,et al, 1997
Frontotemporal Dementia and Early Alzheimer Disease:Differentiation with Frontal Lobe H-1 MR Spectroscopy
Radiology 203:829-836, Ernst,T.,et al, 1997
The Effect of Different Diagnostic Criteria on the Prevalence of Dementia
NEJM 337:1667-1674, Erkinjuntti,T.,et al, 1997
Apolipoprotein E Genotyping in Alzheimer's Disease
Lancet 347:1091-1095, Tanzi,R.,et al, 1996
Noninvasive Perfusion MRI in Alzheimer's Disease:A Preliminary Report
Neurol 47:1339-1342, Sandson,T.A.,et al, 1996
Genetic Factors in Alzheimer's Disease:A Review of Recent Advances
Ann Neurol 40:829-840, Levy-Lahad,E.&Bird,T.D., 1996
Apolipoprotein E Genotyping in the Differential Diagnosis, Not Prediction, of Alzheimer's Disease
Ann Neurol 38:6-14, Roses,A.D., 1995
Apolipoprotein E Genotyping in the Diagnosis of Alzheimer's Disease:A Cautionary View
Ann Neurol 38:2-4, Bird,T.D., 1995
Statement of Use of Apolipoprotein E Testing for Alzheimer Disease
JAMA 274:1627-1629, Farrer,L.A.,et al, 1995
A Low, "Normal"Score on the Mini-Mental State Exam Predicts Development of Dementia after Three Years
JAGS 43:656-661, Braekhus,A.,et al, 1995
Electroencephalography as an Aid in the Exclusion of Alzheimer's Disease
Arch Neurol 51:280-284, Robinson,D.J.,et al, 1994
Anterrater Agreement for Diagnosis of Alzheimer's Disease:The MIRAGE Study
Neurol 44:652-656, Farrer,L.A.,et al, 1994
Management of Neurological Disorders:Dementia
JNNP 57:1451-1456, Rossor,M.N., 1994
Amygdala Atrophy in Alzheimer's Disease, An In Vivo MRI Study
Arch Neurol 50:941-945, Cuenod,C.A.,et al, 1993
Alzheimer's Disease
BMJ 307:779-782, Rossor,M., 1993